Based in the UK, our facility is designed to meet the growing demand for oligonucleotide-based therapies. Equipped with the latest advancements in manufacturing technologies, our facility ensures high-yield, scalable, and cost-efficient production while adhering to the highest standards of safety and compliance.

As nucleic acid therapies continue to evolve, increasing complexity is becoming one of the biggest barriers to successful scale-up. Conjugates, hybrid modalities and advanced delivery systems each require distinct expertise, manufacturing processes and regulatory strategies. CPI helps remove that complexity.

CPI brings together specialist capabilities in synthetic oligonucleotide manufacturing, biologic molecule synthesis and advanced delivery technologies, including lipid nanoparticles (LNPs), to support the seamless development of next-generation RNA, DNA and conjugated therapeutics. From early proof of concept through to GMP manufacture for clinical trials, CPI provides integrated process development, scale-up and analytical expertise under one roof.

Beyond manufacturing, CPI supports regulatory and CMC strategy development, helping ensure that modality selection, delivery systems and process decisions align with a clear and commercially viable route to the clinic. The result is reduced technical risk, accelerated development timelines and a partner with the expertise to scale alongside your science.